Yan Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yan Jin has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
David A. Flockhart
Division of Clinical Pharmacology, Indiana University, School of Medicine, Indianapolis, IN, USA
2 shared publications- Haiwei Gu
College of Health Solutions, Arizona State University, Phoenix, AZ 85004, USA
2 shared publications Janelle Owens
Division of Clinical Pharmacology, Indiana University, School of Medicine, Indianapolis, IN, USA
2 shared publicationsPerry Nystrom
Division of Clinical Pharmacology, Indiana University, School of Medicine, Indianapolis, IN, USA
2 shared publications- Rolf P. Kreutz
Division of Cardiovascular Medicine Indiana Univ. School of Medicine Indianapolis Indiana USA
2 shared publications - Zeruesenay Desta
Department of Pharmacy Practice Purdue University College of Pharmacy West Lafayette Indiana USA
2 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (22) , 2666-2681
The GATA1 N terminus coordinates metabolic reprogramming in erythropoiesis
Mutations in GATA1 that cause skipping of exon 2, which encodes the N terminus, are associated with the myeloid leukemia of Down syndrome and Diamond-Blackfan anemia (DBA). To elucidate the molecular function of this N-terminal region, we used single-cell RNA sequencing (scRNA-seq) on fetal liver cells from Gata1-mutant embryos that express only the short isoform of GATA1 (GATA1s) lacking the N terminus of full-length GATA1 (GATA1FL). scRNA-seq revealed defects in erythropoiesis and aberrant upregulation of glycolytic genes, including PKM, which encodes pyruvate kinase to catalyze the final and irreversible step of glycolysis. Using precision nuclear run-on sequencing and cleavage under targets and release using nuclease (CUT&RUN) after acute GATA1 deletion in erythroid cells, we identified PKM as a direct target of GATA1. Substitution of GATA1FL with GATA1s induced histone lactylation at the PKM promoter, increased pyruvate kinase M (PKM) expression and activity, and enhanced glycolytic flux in erythroid progenitors, without affecting mitochondrial respiration. Importantly, PKM expression is also significantly elevated in patients with DBA with RPS19 mutations, which is associated with reduced levels of GATA1, further supporting a link between GATA1s-driven defective erythropoiesis and dysregulated glycolysis. Together, these findings reveal that GATA1 controls not only heme metabolism but also glycolytic reprogramming.
- 28 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (22) , 2666-2681
Open AccessThe GATA1 N terminus coordinates metabolic reprogramming in erythropoiesis
Mutations in GATA1 that cause skipping of exon 2, which encodes the N terminus, are associated with the myeloid leukemia of Down syndrome and Diamond-Blackfan anemia (DBA). To elucidate the molecular function of this N-terminal region, we used single-cell RNA sequencing (scRNA-seq) on fetal liver cells from Gata1-mutant embryos that express only the short isoform of GATA1 (GATA1s) lacking the N terminus of full-length GATA1 (GATA1FL). scRNA-seq revealed defects in erythropoiesis and aberrant upregulation of glycolytic genes, including PKM, which encodes pyruvate kinase to catalyze the final and irreversible step of glycolysis. Using precision nuclear run-on sequencing and cleavage under targets and release using nuclease (CUT&RUN) after acute GATA1 deletion in erythroid cells, we identified PKM as a direct target of GATA1. Substitution of GATA1FL with GATA1s induced histone lactylation at the PKM promoter, increased pyruvate kinase M (PKM) expression and activity, and enhanced glycolytic flux in erythroid progenitors, without affecting mitochondrial respiration. Importantly, PKM expression is also significantly elevated in patients with DBA with RPS19 mutations, which is associated with reduced levels of GATA1, further supporting a link between GATA1s-driven defective erythropoiesis and dysregulated glycolysis. Together, these findings reveal that GATA1 controls not only heme metabolism but also glycolytic reprogramming.
- Open Access
- 30 August 2024
- Published by Elsevier in Journal of Lipid Research
- Vol. 65 (9) , 100630
Dietary modulation of lung lipids influences inflammatory responses to inhaled ozone
- 30 August 2024
- Published by Elsevier in Journal of Lipid Research
- Vol. 65 (9) , 100630
Open AccessDietary modulation of lung lipids influences inflammatory responses to inhaled ozone
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Loss of Fatty Acid Degradation by Astrocytic Mitochondria as a Mechanism of Neuroinflammation and Neurodegeneration
Background: Astrocytes provide key neuronal support, and their phenotypic transformation is strongly implicated in neurodegenerative disorders including Alzheimer’s disease (AD). Metabolically, astrocytes possess modest mitochondrial oxidative phosphorylation (OxPhos) activity, yet the pathological role of astrocytic OxPhos in neurodegeneration remains to be defined.Method: We generated the TfamAKO mice, in which the transcription factor A mitochondrial (Tfam) is deleted selectively in astrocytes. Behavioral, electrophysiological, immunostaining, transcriptomics, metabolomics, and magnetic resonance imaging analyses were employed to characterize AD‐relevant phenotypes of TfamAKO mice, which were further compared to an AD mouse model (5xFAD). Primary cell cultures and co‐cultures were used to determine the cell autonomous and non‐autonomous mechanisms by which disrupted astrocytic OxPhos induces astrocyte reactivity, neuroinflammation and neurodegeneration.Result: Here we show that the brain critically depends on astrocytic OxPhos to degrade fatty acids (FAs) and maintain lipid homeostasis. Aberrant astrocytic OxPhos induces lipid droplet (LD) accumulation followed by neurodegeneration that recapitulates key features of AD including reactive astrogliosis, synaptic loss, microgliosis, demyelination, and cognitive impairment. Mechanistically, when FA load overwhelms astrocytic OxPhos capacity, elevated acetyl‐CoA levels induce astrocyte reactivity by enhancing STAT3 acetylation and activation. Intercellularly, lipid‐laden reactive astrocytes stimulate neuronal FA oxidation and oxidative stress, activate microglia via IL‐3 signaling, and inhibit the biosynthesis of FAs and phospholipids required for myelin replenishment. Moreover, the metabolic and transcriptional signatures of the hippocampus of TfamAKO mice highly overlap with that of 5xFAD mice.Conclusion: We reveal a lipid‐centric, AD‐resembling mechanism by which astrocytic mitochondrial dysfunction progressively induces neuroinflammation and neurodegeneration.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessLoss of Fatty Acid Degradation by Astrocytic Mitochondria as a Mechanism of Neuroinflammation and Neurodegeneration
Background: Astrocytes provide key neuronal support, and their phenotypic transformation is strongly implicated in neurodegenerative disorders including Alzheimer’s disease (AD). Metabolically, astrocytes possess modest mitochondrial oxidative phosphorylation (OxPhos) activity, yet the pathological role of astrocytic OxPhos in neurodegeneration remains to be defined.Method: We generated the TfamAKO mice, in which the transcription factor A mitochondrial (Tfam) is deleted selectively in astrocytes. Behavioral, electrophysiological, immunostaining, transcriptomics, metabolomics, and magnetic resonance imaging analyses were employed to characterize AD‐relevant phenotypes of TfamAKO mice, which were further compared to an AD mouse model (5xFAD). Primary cell cultures and co‐cultures were used to determine the cell autonomous and non‐autonomous mechanisms by which disrupted astrocytic OxPhos induces astrocyte reactivity, neuroinflammation and neurodegeneration.Result: Here we show that the brain critically depends on astrocytic OxPhos to degrade fatty acids (FAs) and maintain lipid homeostasis. Aberrant astrocytic OxPhos induces lipid droplet (LD) accumulation followed by neurodegeneration that recapitulates key features of AD including reactive astrogliosis, synaptic loss, microgliosis, demyelination, and cognitive impairment. Mechanistically, when FA load overwhelms astrocytic OxPhos capacity, elevated acetyl‐CoA levels induce astrocyte reactivity by enhancing STAT3 acetylation and activation. Intercellularly, lipid‐laden reactive astrocytes stimulate neuronal FA oxidation and oxidative stress, activate microglia via IL‐3 signaling, and inhibit the biosynthesis of FAs and phospholipids required for myelin replenishment. Moreover, the metabolic and transcriptional signatures of the hippocampus of TfamAKO mice highly overlap with that of 5xFAD mice.Conclusion: We reveal a lipid‐centric, AD‐resembling mechanism by which astrocytic mitochondrial dysfunction progressively induces neuroinflammation and neurodegeneration.
- 28 June 2023
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 166
Recent review on selected xenobiotics and their impacts on gut microbiome and metabolome
- 28 June 2023
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 166
Recent review on selected xenobiotics and their impacts on gut microbiome and metabolome
- 13 May 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (S1)
Targeted Metabolomics Reveals Plasma Biomarkers and Metabolic Alterations of the Aging Process in Healthy Young and Older Adults
With the exponential rise in the older population for the coming years, many studies have aimed to further investigate potential solutions to the aging process. It has been well understood that age is the largest risk factor for chronic disease due to younger individuals possessing more prevalent and adaptive metabolic networks that result in overall health and homeostasis. During the lifecycle, several physiological alterations ensue throughout the metabolic system that attribute to functional decline. In this cross‐sectional analysis, a targeted metabolomic approach was applied to investigate the plasma metabolome of 151 young (n = 75) and older adults (n = 76). A corrected MANOVA model was generated, with such covariates as gender, BMI, and chronic condition score (CCS), to analyze the aging process of the two populations. Metabolites associated with impaired fatty acid metabolism were found to be most significant: palmitic acid ( p < 0.001), 3‐hexenedioic acid ( p < 0.001), stearic acid ( p = 0.005), and decanoylcarnitine ( p = 0.036). Derivatives of amino acid metabolism, 1‐methlyhistidine ( p = 0.035) and methylhistamine ( p = 0.027), were found to be increased in the younger population and several novel metabolites were identified, such as cadaverine ( p = 0.034), 4‐ethylbenzoic acid ( p = 0.029), and 3‐hexenedioic acid ( p < 0.001). Principal component analysis was conducted and highlighted a shift in the metabolome for both groups. Pathway and enrichment analyses uncovered several impacted pathways that elucidate the metabolic alterations in the older population and aid in further explanation of the aging process. As a result, we offer a better understanding of the aging metabolome and potentially reveal new biomarkers for future study.
- 13 May 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (S1)
Targeted Metabolomics Reveals Plasma Biomarkers and Metabolic Alterations of the Aging Process in Healthy Young and Older Adults
With the exponential rise in the older population for the coming years, many studies have aimed to further investigate potential solutions to the aging process. It has been well understood that age is the largest risk factor for chronic disease due to younger individuals possessing more prevalent and adaptive metabolic networks that result in overall health and homeostasis. During the lifecycle, several physiological alterations ensue throughout the metabolic system that attribute to functional decline. In this cross‐sectional analysis, a targeted metabolomic approach was applied to investigate the plasma metabolome of 151 young (n = 75) and older adults (n = 76). A corrected MANOVA model was generated, with such covariates as gender, BMI, and chronic condition score (CCS), to analyze the aging process of the two populations. Metabolites associated with impaired fatty acid metabolism were found to be most significant: palmitic acid ( p < 0.001), 3‐hexenedioic acid ( p < 0.001), stearic acid ( p = 0.005), and decanoylcarnitine ( p = 0.036). Derivatives of amino acid metabolism, 1‐methlyhistidine ( p = 0.035) and methylhistamine ( p = 0.027), were found to be increased in the younger population and several novel metabolites were identified, such as cadaverine ( p = 0.034), 4‐ethylbenzoic acid ( p = 0.029), and 3‐hexenedioic acid ( p < 0.001). Principal component analysis was conducted and highlighted a shift in the metabolome for both groups. Pathway and enrichment analyses uncovered several impacted pathways that elucidate the metabolic alterations in the older population and aid in further explanation of the aging process. As a result, we offer a better understanding of the aging metabolome and potentially reveal new biomarkers for future study.
- Open Access
- 30 September 2016
- Published by Springer Nature
- p. 191-204
Toward a Parallel Turing Machine Model
- 30 September 2016
- Published by Springer Nature
- p. 191-204
Open AccessToward a Parallel Turing Machine Model
- Open Access
- 15 May 2014
- Published by Taylor & Francis in Platelets
- Vol. 26 (4) , 358-363
Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel
It has been estimated that up to half of circulating factor XIIIa (FXIIIa) is stored in platelets. The release of FXIIIa from platelets upon stimulation with adenosine diphosphate (ADP) in patients with coronary artery disease treated with dual antiplatelet therapy has not been previously examined. Samples from 96 patients with established coronary artery disease treated with aspirin and clopidogrel were examined. Platelet aggregation was performed by light transmittance aggregometry in platelet-rich plasma (PRP), with platelet-poor plasma (PPP) as reference, and ADP 5 µM as agonist. Kaolin-activated thrombelastography (TEG) was performed in citrate PPP. PRP after aggregation was centrifuged and plasma supernatant (PSN) collected. FXIIIa was measured in PPP and PSN. Platelet aggregation after stimulation with ADP 5 µM resulted in 24% additional FXIIIa release in PSN as compared to PPP (99.3 ± 27 vs. 80.3 ± 24%, p < 0.0001). FXIIIa concentration in PSN correlated with maximal plasma clot strength (TEG-G) (r = 0.48, p < 0.0001), but not in PPP (r = 0.15, p = 0.14). Increasing quartiles of platelet-derived FXIIIa were associated with incrementally higher TEG-G (p = 0.012). FXIIIa release was similar between clopidogrel responders and non-responders (p = 0.18). In summary, platelets treated with aspirin and clopidogrel release a significant amount of FXIIIa upon aggregation by ADP. Platelet-derived FXIIIa may contribute to differences in plasma TEG-G, and thus, in part, provide a mechanistic explanation for high clot strength observed as a consequence of platelet activation. Variability in clopidogrel response does not significantly influence FXIIIa release from platelets.
- 15 May 2014
- Published by Taylor & Francis in Platelets
- Vol. 26 (4) , 358-363
Open AccessPlatelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel
It has been estimated that up to half of circulating factor XIIIa (FXIIIa) is stored in platelets. The release of FXIIIa from platelets upon stimulation with adenosine diphosphate (ADP) in patients with coronary artery disease treated with dual antiplatelet therapy has not been previously examined. Samples from 96 patients with established coronary artery disease treated with aspirin and clopidogrel were examined. Platelet aggregation was performed by light transmittance aggregometry in platelet-rich plasma (PRP), with platelet-poor plasma (PPP) as reference, and ADP 5 µM as agonist. Kaolin-activated thrombelastography (TEG) was performed in citrate PPP. PRP after aggregation was centrifuged and plasma supernatant (PSN) collected. FXIIIa was measured in PPP and PSN. Platelet aggregation after stimulation with ADP 5 µM resulted in 24% additional FXIIIa release in PSN as compared to PPP (99.3 ± 27 vs. 80.3 ± 24%, p < 0.0001). FXIIIa concentration in PSN correlated with maximal plasma clot strength (TEG-G) (r = 0.48, p < 0.0001), but not in PPP (r = 0.15, p = 0.14). Increasing quartiles of platelet-derived FXIIIa were associated with incrementally higher TEG-G (p = 0.012). FXIIIa release was similar between clopidogrel responders and non-responders (p = 0.18). In summary, platelets treated with aspirin and clopidogrel release a significant amount of FXIIIa upon aggregation by ADP. Platelet-derived FXIIIa may contribute to differences in plasma TEG-G, and thus, in part, provide a mechanistic explanation for high clot strength observed as a consequence of platelet activation. Variability in clopidogrel response does not significantly influence FXIIIa release from platelets.
- Open Access
- 9 February 2014
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 38 (3) , 380-387
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease
Factor XIII (FXIII) is necessary for cross linking of fibrin strands and generation of stable fibrin clot. FXIII Val34Leu is a common genetic single nucleotide polymorphism that has been associated with accelerated fibrin stabilization and reduced rate of fibrinolysis. The contribution of Val34Leu to long term risk of recurrent myocardial infarction (MI) in patients with coronary stenting has not been conclusively established. The objective of the study was to examine the effects of Val34Leu on fibrin generation, platelet aggregation, and long term clinical outcomes in patients with coronary artery disease treated with dual antiplatelet therapy. Patients with angiographically documented coronary artery disease who were treated with aspirin and clopidogrel were enrolled (n = 211). Light transmittance aggregometry and plasma fibrin clot formation using thrombelastography (TEG) were determined. Genotyping of Val34Leu was performed using Taqman assay. Clinical events during follow up were recorded. Homozygous carriers of 34Leu variant had significantly shorter fibrin clot formation time as compared to wild type individuals (TEG K: 1.27 ± 0.3 vs. 1.68 ± 1.1 min, p = 0.011). The Val34Leu variant was associated with gene dose dependent increased risk of MI (log rank, p = 0.002) or occurrence of composite of MI and CV death (log rank, p = 0.005) with highest event rates observed in homozygous carriers of 34Leu. In summary, FXIII Val34Leu polymorphism was associated with increased rate of fibrin stabilization in homozygous carriers of the variant and may increase risk of recurrent MI and death in patients with angiographically established coronary artery disease treated with dual antiplatelet therapy.
- 9 February 2014
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 38 (3) , 380-387
Open AccessFactor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease
Factor XIII (FXIII) is necessary for cross linking of fibrin strands and generation of stable fibrin clot. FXIII Val34Leu is a common genetic single nucleotide polymorphism that has been associated with accelerated fibrin stabilization and reduced rate of fibrinolysis. The contribution of Val34Leu to long term risk of recurrent myocardial infarction (MI) in patients with coronary stenting has not been conclusively established. The objective of the study was to examine the effects of Val34Leu on fibrin generation, platelet aggregation, and long term clinical outcomes in patients with coronary artery disease treated with dual antiplatelet therapy. Patients with angiographically documented coronary artery disease who were treated with aspirin and clopidogrel were enrolled (n = 211). Light transmittance aggregometry and plasma fibrin clot formation using thrombelastography (TEG) were determined. Genotyping of Val34Leu was performed using Taqman assay. Clinical events during follow up were recorded. Homozygous carriers of 34Leu variant had significantly shorter fibrin clot formation time as compared to wild type individuals (TEG K: 1.27 ± 0.3 vs. 1.68 ± 1.1 min, p = 0.011). The Val34Leu variant was associated with gene dose dependent increased risk of MI (log rank, p = 0.002) or occurrence of composite of MI and CV death (log rank, p = 0.005) with highest event rates observed in homozygous carriers of 34Leu. In summary, FXIII Val34Leu polymorphism was associated with increased rate of fibrin stabilization in homozygous carriers of the variant and may increase risk of recurrent MI and death in patients with angiographically established coronary artery disease treated with dual antiplatelet therapy.
- 1 February 2008
- Published by Elsevier in Journal of Adolescent Health
- Vol. 42 (2) , 28-29
32: Vaccine-Type HPV Infection and Post-Licensure Attitudes About HPV Vaccination in Young Women
- 1 February 2008
- Published by Elsevier in Journal of Adolescent Health
- Vol. 42 (2) , 28-29
32: Vaccine-Type HPV Infection and Post-Licensure Attitudes About HPV Vaccination in Young Women
- 1 April 2005
- Published by Elsevier in Desalination
- Vol. 174 (3) , 237-245
Desalination by electret technology
- 1 April 2005
- Published by Elsevier in Desalination
- Vol. 174 (3) , 237-245
Desalination by electret technology